Whole-body hyperthermia in the scope of von Ardenne's systemic cancer multistep therapy (sCMT) combined with chemotherapy in patients with metastatic colorectal cancer: a phase I/II study

References

• Holen KD, Saltz LB. New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer. Lancet Oncol 2001; 2: 290–7.
   PubMed Web of Science ®Google Scholar
• Tebbutt NC, Cattell E, Midgley R, Cunningham D, Kerr D. Systemic treatment of colorectal cancer. Eur J Cancer 2002; 38: 1000–15.
   PubMed Web of Science ®Google Scholar
• Richards F, II, Case LD, White DR, Muss HB, Spurr CL, Jackson DV, Cooper MR, Zekan P, Cruz J, Stuart JJ, et al. Combination chemotherapy (5-fluorouracil, methyl-CCNU, mitomycin C) versus 5-fluorouracil alone for advanced previously untreated color-ectal carcinoma. A phase III study of the Piedmont Oncology Association. J Clin Oncol 1986; 4: 565–70.
   PubMed Web of Science ®Google Scholar
• Ross P, Norman A, Cunningham D, Webb A, Iveson T, Padhani A, Prendiville J, Watson M, Massey A, Popescu R, Oates J. A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol 1997; 8: 995–1001.
   Google Scholar
• Dahl O. Interaction of heat and drugs in vitro and in vivo. In: Vernon CC, ed. Therrnoradiotherapy and Therrnochernotherapy. Berlin: Springer, 1995; 103–21.
   Google Scholar
• Hahn GM, Li GC. Interactions of hyperthermia and drugs: treatments and probes. Natl Cancer Inst Monogr 1982; 61: 217–21.
   Google Scholar
• Witkamp AJ, de Bree E, Kaag MM, Boot H, Beijnen JH, van Slooten GW, van Coevorden F, Zoetmulder FA. Extensive cytoreductive surgery followed by intra-opera-five hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peri-toneal carcinomatosis of colorectal origin. Eur J Cancer 2001; 37: 979–84.
   PubMed Web of Science ®Google Scholar
• Atanackovic D, Nierhaus A, Neumeier M, Hossfeld DK, Hegewisch-Becker S. 41.8 degrees C whole body hyperthermia as an adjunct to chemotherapy induces prolonged T cell activation in patients with various malignant diseases. Cancer Irnrnunol Immunother 2002; 51: 603–13.
   Google Scholar
• Hildebrandt B, Wust P, Ahlers O, Dieing A, Sreenivasa G, Kerner T, Felix R, Riess H. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hernatol 2002; 43: 33–56.
   PubMed Web of Science ®Google Scholar
• Robins HI, Kutz M, Wiedemann GJ, Katschinski DM, Paul D, Grosen E, Tiggelaar CL, Spriggs D, Gillis W, D'Oleire F. Cytokine induction by 41.8 degrees C whole body hyperthermia. Cancer Lett 1995; 97: 195–201.
   Google Scholar
• Falk MH, Issels RD. Hyperthermia in oncology. Int j Hyperthermia 2001; 17: 1–18.
   PubMed Web of Science ®Google Scholar
• Wust P, Hildebrandt B, Sreenivasa G, Rau B, Gellermann J, Riess H, Schlag P. Hyperthermia in combined treatment of cancer. Lancet Oncol 2002; 3: 487–97.
   Google Scholar
• Kerner T, Deja M, Gerlach H, Ahlers O, Löffel J, Wust P, Hildebrandt B, Felix R, Riess H. Whole-body hyperthermiaa secure procedure for patients with various malignancies?Intensive Care Med 1999; 25: 959–65.
   Google Scholar
• Robins HI, Dennis WH, Neville AJ, Shecterie LM, Martin PA, Grossmann J, Davis TE, Neville SR, Gillis WK, Rusy BF. A nontoxic system for 41.8°C whole body hyperthermia: results of a phase I study using a radiant heat device. Cancer Res 1985; 45: 3937–44.
   Google Scholar
• Robins HL, Cohen JD, Schmitt CL, Tutsch KD, Feierabend C, Arzoomanian RZ, Alberti D, D'Oleire F, Longo W, Heiss C, Rushing D, Love R, Spriggs D. Phase I clinical trial of carboplatin and 41.8°C whole-body hyperthermia in cancer patients. J Clin Oncol 1993; 9: 1787–94.
   Google Scholar
• Bakhshandeh A, Bruns I, Traynor A, Robins HI, Eberhardt K, Demedts A, Kaukel E, Koschel G, Gatzemeier U, Kohlmann T, Dalhoff K, Ehlers EM, Gruber Y, Zumschlinge R, Hegewisch-Becker S, Peters SO, Wiedemann GJ. Ifosfamide, carboplatin and etoposide combined with 41.8 degrees C whole body hyperthermia for malignant pleural mesothelioma. Lung Cancer 2003; 39: 339–45.
   Google Scholar
• Hegewisch-Becker S, Gruber Y, Corovic A, Pichlmeier U, Atanackovic D, Nierhaus A, Hossfeld D. Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxali-platin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study. Ann Oncol 2002; 13: 1197–204.
   Google Scholar
• Strobl B, Janni W, Rjosk D, Rack BK, Kornya L, Bakhshandeh-Bath A, Hegewisch-Becker S, Hildebrandt B, Sommer HL. Chemotherapy with carboplatin/ifosfamide combined with whole body hyperthermia in recurrent ovarian cancerresults of a phase IIstudy (Dolphin-I-study). J. Clin Oncol 2002; 19:A2523
   Google Scholar
• Westermann AM, Grosen EA, Katschinski DM, Jager D, Rietbroek R, Schink JC, Tiggelaar CL, Jager E, Zum Vorde sive Vording P, Neuman A, Knuth A, Van Dijk JD, Wiedemann GJ, Robins HI. A pilot study of whole body hyperthermia and carbo-platin in platinum-resistant ovarian cancer. Eur J Cancer 2001; 37: 1111–17.
   Google Scholar
• Westermann AM, Wiedemann GJ, Jager E, Jager D, Katschinski DM, Knuth A, Vorde Sive Vording PZ, Van Dijk JD, Finet J, Neumann A, Longo W, Bakhshandeh A, Tiggelaar CL, Gillis W, Bailey H, Peters SO, Robins HI. A Systemic Hyperthermia Oncologic Working Group trial. Ifosfamide, carboplatin, and etoposide combined with 41.8 degrees C whole-body hyperthermia for metastatic soft tissue sarcoma. Oncology 2003; 64: 312–21.
   Google Scholar
• Von Ardenne M. Principles and concept 1993 of the systemic cancer multistep therapy (sCMT). Strahlenther Onkol 1994; 170: 581–9.
   PubMedGoogle Scholar
• Wust P, Riess H, Hildebrandt B, Loffel J, Deja M, Ahlers O, Kener T, Ardenne A, Felix R. Utilizing the Iratherm-2000 infrared system for whole-body hyperthermia at 42°Ca feasibility study. Int J Hypertherrnia 2000; 16: 325–39.
   Google Scholar
• Kerner T, Deja M, Ahlers O, Hildebrandt B, Dieing A, Riess H, Wust P, Gerlach H. Monitoring arterial blood pressure during whole body hyperthermia. Acta Anaesthesiol Scand 2002; 46: 561–6.
   PubMedGoogle Scholar
• Kerner T, Hildebrandt B, Ahlers O, Deja M, Riess H, Draeger J, Wust P, Gerlach H. Anaesthesiological experiences in whole-body hyperthermia. Int J Hypertherrnia 2002; 1–12.
   PubMedGoogle Scholar
• Kreyszig E. Statistical Methods and their Applications. Goettingen: Vandenhoeck & Ruprecht, 1972 [in German].
   Google Scholar
• Robins HI, Rushing D, Kutz M, Tutsch KD, Tiggelaar CL, Paul D, Spriggs D, Kraemer C, Gillis W, Feierabend C, Arzoomanian RZ, Longo W, Alberti D, d'Oliere F, Qu RP, Wilding G, Steart JA. Phase I clinical trial of melphalan and 41.8°C whole-body hyperthermia in cancer patients. J Clin Oncol 1997; 15: 158–64.
   PubMed Web of Science ®Google Scholar
• Hildebrandt B. Clinical trials on whole-body hyperthermia combined with chemotherapy. Onkologie 2002; 25: A912.
   Google Scholar
• Pereira Arias AM, Wester JP, Blankendaal M, Schilthuis MS, Kuijper EJ, Rademaker BM, Stoutenbeek C, Rietbroek R. Multiple organ dysfunction syndrome induced by whole-body hyperthermia and polychemotherapy in a patient with disseminated leiomyosarcoma of the uterus. Intensive Care Med 1999; 25: 1013–16.
   PubMed Web of Science ®Google Scholar
• Wiedemann GJ, Robins HI, Gutsche S, Mentzel M, Deeken M, Katschinsky DM, Eleftheriadis S, Crahe R, Weiss C, Storer B, Wagner T. Ifosfamide, carboplatin and etoposide (ICE) combined with 41.8°C whole body hyperthermia in patients with refrac-tory sarcoma. Eur J Cancer 1996; 32A: 888–92.
   Google Scholar